Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2021
August 25, 2021 at 11:24 am
Share
Sunflower Pharmaceutical Group Co.,Ltd announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 2,101.740 million compared to CNY 1,600.107 million a year ago. Operating income was CNY 350.026 million compared to CNY 323.841 million a year ago. Net income was CNY 307.301 million compared to CNY 237.075 million a year ago. Basic earnings per share from continuing operations was CNY 0.53 compared to CNY 0.41 a year ago.
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD is a China-based company principally engaged in the research, development, manufacture and sale of Chinese patent drugs, chemical drugs, biopharmaceuticals and health products. The Company provides drugs in six categories, including digestive medicine, pediatric medicine, gynecological medicine, rheumatoid bone medication, breathing cold medication and cardiovascular drugs. The Companyâs main products include Weikangling capsules, liver tablets, hyperactivity cough oral liquid for children use, pediatric Huatanzhike particles, Kangfu anti-inflammatory suppository and pediatric paracetamol particles, among others. The Company distributes its products in domestic market.
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD 
